J&J boosts litigation settlement reserve by $600mn
This article was originally published in Scrip
Executive Summary
Rumors that emerged in March may be on the mark that Johnson & Johnson could be paying nearly double the $1 billion it reportedly agreed on with the US Department of Justice (DOJ) to settle charges of illegal off-label promotion of the company's schizophrenia and bipolar drug Risperdal (risperidone), with the firm revealing it had set aside an additional $600 million (scripintelligence, 19 March 2012).